Arcutis insider plans Rule 144 sale of 10,000 shares

Arcutis Biotherapeutics insider Howard Welgus filed a Rule 144 notice to sell 10,000 shares of common stock through Merrill, with an aggregate market value of $250,482.69.

Rhea-AI Filing Summary

Arcutis Biotherapeutics insider Howard Welgus filed a Rule 144 notice to sell 10,000 shares of common stock through Merrill, with an aggregate market value of $250,482.69. The shares relate to a stock option exercise on 06/04/2018, paid in cash.

Welgus reports prior sales over the past three months of 10,000 shares each on 11/03/2025, 12/01/2025, and 01/02/2026, with gross proceeds of $252,668.51, $302,133.02, and $289,606.03. The planned sale is expected around 02/02/2026 on NASDAQ, where 122,492,192 shares of the issuer’s common stock are outstanding.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing by Howard Welgus for ARQT disclose?

The filing discloses that Howard Welgus plans to sell 10,000 Arcutis Biotherapeutics common shares under Rule 144. The planned sale is through Merrill on NASDAQ, with an aggregate market value of $250,482.69 based on the figures reported in the notice.

How many Arcutis (ARQT) shares has Howard Welgus recently sold?

The notice lists three recent sales of 10,000 Arcutis common shares each. These occurred on 11/03/2025, 12/01/2025, and 01/02/2026, generating gross proceeds of $252,668.51, $302,133.02, and $289,606.03, respectively, over the prior three-month period.

At what price level is the new 10,000-share ARQT sale estimated?

The planned 10,000-share sale has an aggregate market value of $250,482.69. This value comes directly from the Rule 144 notice and reflects the filer’s estimate for the transaction reported through Merrill on NASDAQ.

How were the Arcutis (ARQT) shares being sold by Howard Welgus acquired?

The 10,000 Arcutis common shares were acquired on 06/04/2018 via a stock option exercise. The filing states the transaction was completed for cash on that date, indicating a standard option exercise followed by the planned resale under Rule 144.

How many Arcutis Biotherapeutics shares are outstanding according to this notice?

The notice reports that 122,492,192 Arcutis Biotherapeutics common shares are outstanding. This figure provides context for the size of the 10,000-share planned sale relative to the company’s total outstanding common stock base.

When is the planned Rule 144 sale of ARQT shares expected to occur?

The filing lists an approximate sale date of 02/02/2026 for the 10,000 Arcutis common shares. The transaction is expected to take place on NASDAQ, with Merrill identified as the broker handling the planned sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 05:04 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001801050
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Arcutis Biotherapeutics, Inc.
SEC File Number	001-39186
Address of Issuer	3027 Towns gate Rd Ste 300 Westlake Village CALIFORNIA 91361
Phone	805-418-5006
Name of Person for Whose Account the Securities are To Be Sold	Howard Welgus
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill 8890 Lyra Dr 5th Floor Columbus OH 43215	10000	250482.69	122492192	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/04/2018	Stock option exercise	Arcutis Biotherapeutics Inc			10000	06/04/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	01/02/2026	10000	289606.03
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	11/03/2025	10000	252668.51
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	12/01/2025	10000	302133.02

144: Remarks and Signature

Remarks
Date of Notice	02/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/11/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Howard Welgus
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)